Our latest videos
Non Regulatory September 29, 2021Nanoform receives funding to solve challenges for global health
Regulatory September 24, 2021Nanoform Finland Plc – Manager’s transactions – Gonçalo Andrade
Non Regulatory September 23, 2021Nanoform shortlisted for the European Small and Mid-Cap Awards 2021
Nanoform Finland Plc (“Nanoform”), published its Q2/2021 report on August 26, 2021, at 8.10 a.m. Finnish time / 7.10 a.m. Swedish time. The company will hold a conference call and an online presentation on the same day at 3.00 p.m. Finnish time / 2.00 p.m. Swedish time.
Nanoform is an innovative nanoparticle medicine enabling company that supplies best in class nanoforming services. Our multi-patented CESS® technology can double the amount of lead compounds progressing into clinic, leading to a significant increase in the number of drugs that reach the market. The green particle engineering process produces pure and stable nanoparticles as small as 10 nm using supercritical carbon dioxide.
Our work enables our partners to overcome drug development challenges to rapidly progress novel drugs to market. We are driven by a passion for innovation, and constantly work to find ground-breaking solutions that enhance drug effectiveness and targeting.
Our nanoforming services provide solutions to complex formulation challenges by increasing drug solubility and bioavailability. The advanced production of nanoparticles provides pharmacokinetic improvements, commercial opportunities and novel avenues for drug delivery.
We have established a multidisciplinary team that brings together world-class scientists with experts in pharmaceutical business development. Every member of the team is committed to the enhancement of drug compounds for swift progression to the market.
Working together for enhanced drug development
We work with our partners to successfully nanoformTM APIs for a range of therapeutic areas. Together, we can develop life changing medicines that will reach patients across the globe.
Nanoform’s platform is exciting for its broad applicability to drug development across all therapeutic areas